Half Year Results Presentation
Filed with ASX · · 7 pages · English
Interim Results H1 FY20 Highlights Positive EBITDA of $0.6 Million for the period ended 31 December 2019 Including a one-time revenue adjustment, IDT generated a positive EBITDA of $0.6 million representing a year-on-year improvement of 155% ($1.1 million EBITDA loss reported as at 31 December 2018) IDT base business results reflect gross margin improvement and ongoing cost control initiatives Exc
In the deck
Story so far
Earlier from IDT Australia
- Appendix 4D
- Commercial-Scale GMP Medicinal Cannabis Resin Extraction
- Termination of Distribution Agreement
- Australian produced medicinal cannabis product
- Investor and Medicinal Cannabis Update
Later from IDT Australia
- Medicinal Cannabis GMP manufacturing update
- Business Update - COVID-19
- Cann Group Executes New Export Supply Agreements
- Appendix 4E
- IDT Australia Investor Highlights 2020
Follow IDT Australia into a list and get an email when it puts out news.
Follow IDT Australia